It has been shown that there is a window of opportunity for treatment in Rheumatoid Arthritis (RA). Several Argentinean studies showed an average of 8 months to arrive to a rheumatology visit and 12 months to receive DMARDs. There aren't recent studies. Objectives: To establish delay time from onset of rheumatoid arthritis (RA) symptoms to the first rheumatology visit, to diagnosis of the disease and to the beginning of treatment with DMARDs; and to assess impact of such delay on structural damage, in a cohort of RA patients. Methods: A retrospective study was performed including all patients with RA (fulfilling ACR/EULAR 2010 criteria) seen at a Prepaid Medical Health Plan between 2002-2015. Diagnosis delay and its impact on functional capacity measured by HAQ-A and structural damage by Sharp van der Hejde score (SvdH) was estimated. Demographic and clinical data, and dates ofdiagnosis, onset of symptoms and HAQ-A were extracted from electronic medical records. Svdh score was performed by an experienced rheumatologist. Results: 246 patients (mean age at diagnosis 67.25±14 years, 199 (81%) female) were included. Clinical presentation was poliarticularin 49% of the cases, oligoarticularin 47% and monoarticular in 3%. 79% had high titers of anti-cyclic citrullinated peptide antibodies, 12% low titers, and 9% were negative. Rheumatoid factor was positive in 82.5%. Mean time of follow up was 7 years (SD: 3.8). At the end of the follow-up,median HAQ-A (n=145) was 0.125 (IRQ: 0-0.87). Hands and feet lastxray available were analized in 171 patients. Median Svdh score was 15 (IQR: 6-33). 242 patients (98.4%) received DMARDs as initial treatment: methotrexate monotherapy (76%) was the most frequent one. 41 patients (17%) received biological agents at some point of their disease. Table 1 shows different delay times in accessing rheumatology consultation, diagnosis and beginning of treatment. At the end of follow up, 21 patients (12.28%) had noradiological damage (Svdh score =0). In the ROC curve (AUC 0.57,95% CI: 0.45 -0.69), 5.6 months of diagnosis delay was the best cut off valueto discriminate the presence of erosions (SvdH erosions score>0), with a sensitivity and specificity of 54.17% and 61.90%, respectively. Delay in diagnosis greater than 12 months (n=70) was associated with significantly radiological damage: Svdh mean 30.91 ); p=0.0325. Conclusions: In a Prepaid Medical Health Planwith ease of referral, there is still a significant delay in diagnosis and treatment of RA patients.Delay in diagnosis greater than 12 months was associated with more radiological damage.
Background: The level of vascular endothelial growth factor (VEGF) may reflect the intensity of angiogenesis, which is an important step in the initiation and development of chronic rheumatoid arthritis (RA). Objectives: to study features of VEGF level changes in the blood of RA patients, depending on the duration of the disease, the degree of activity, the level of antibodies to cyclic citrullinated peptide (anti-CCP) Methods: 194 patients were examined with a diagnosis of RA (verified according to criteria ACR/EULAR 2010), without concomitant pathology. Among the examined patients with RA women predominated 168 (86.6%), and there were 26 men (13.4%). The age of patients was 22 to 65 years (mean age 47,7±10,22 years), mean duration of the disease was 3,82±3,43 years. Assessment of RA activity was done by DAS 28 index, using blood CRP in the formula. 152 patients were positive for the presence of anti-CCP (≥20 U/ml) (78%) and 42 (22%) -negative. Serum CRP concentrations (Vector-Best, Russia), anti-CCP (Orgentec, Germany), VEGF (BCM Diagnostic, Canada) were determined by ELISA. Statistical processing of the data was performed using non-parametric methods, univariate (ANOVA) variance analysis on a personal computer using a licensed software packages ("Microsoft-Excel" and "Statistica-Stat-Soft", USA) Results: Analysis of VEGF level changes in the blood depending on the duration of RA revealed that the measure was high in patients with small diseases duration 0-23 months (472.96 (341.1; 582.1) pg/ml) compared with the group 5 years (324.1 (199.2; 556.2) pg/ml) (p<0,04). Analysis of VEGF level in blood depending on the degree of RA activity showed that the VEGF concentration in blood increased with increasing degree of RA activity and it was the greatest -564.4 (340.1; 758.4) pg/ml in the group with a high degree (DAS28 >5.2) compared to the minimum (DAS28 ≤3,2) -230,5 (178,1; 385,3) pg/ml, and moderate (DAS28 3,3-5,2) -356,4 (278 9; 553.1) pg/ml, (p<0,001; p=0,005, respectively). Using ANOVA variance analysis, it was found that the degree of RA activity influenced the VEGF levels in the blood (KW =17,37; p<0,001). Analysis of the VEGF levels in the blood depending on the level of anti-CCP
